<code id='AAAFAF23C1'></code><style id='AAAFAF23C1'></style>
    • <acronym id='AAAFAF23C1'></acronym>
      <center id='AAAFAF23C1'><center id='AAAFAF23C1'><tfoot id='AAAFAF23C1'></tfoot></center><abbr id='AAAFAF23C1'><dir id='AAAFAF23C1'><tfoot id='AAAFAF23C1'></tfoot><noframes id='AAAFAF23C1'>

    • <optgroup id='AAAFAF23C1'><strike id='AAAFAF23C1'><sup id='AAAFAF23C1'></sup></strike><code id='AAAFAF23C1'></code></optgroup>
        1. <b id='AAAFAF23C1'><label id='AAAFAF23C1'><select id='AAAFAF23C1'><dt id='AAAFAF23C1'><span id='AAAFAF23C1'></span></dt></select></label></b><u id='AAAFAF23C1'></u>
          <i id='AAAFAF23C1'><strike id='AAAFAF23C1'><tt id='AAAFAF23C1'><pre id='AAAFAF23C1'></pre></tt></strike></i>

          Home / explore / focus

          focus


          focus

          author:Wikipedia    Page View:93953
          Adobe

          LONDON — GSK said Tuesday it would purchase the asthma-focused drug developer Aiolos Bio for $1 billion upfront, the latest in a string of pharma acquisitions that are bolstering hopes for the industry’s year ahead.

          The deal includes up to another $400 million in payments if certain milestones are met.

          advertisement

          Aiolos was launched just last year, based in both San Francisco and London. The company, which announced a $245 million Series A round in October, has been readying a Phase 2 trial of its candidate AIO-001 in adult asthma.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In